Related Experiment Video
Updated: Aug 3, 2026
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells
1Institute on Aging, University of Wisconsin-Madison, Madison 53706, USA.
Abstract:
IL-6 stimulates proliferation of various tumors, including lymphoma and myeloma; thus, inhibiting IL-6 may decrease the growth of these tumors. Accordingly, we examined the effect of IL-6 and IL-6R antisense phosphorothioated oligodeoxynucleotides (ODNs) on proliferation of IL-6 responsive (U266) and nonresponsive (RPMI 8226) myeloma cell lines. Cells were grown in the presence or absence of IL-6, with added antisense to either IL-6 or IL-6R. Cells were evaluated for proliferation ([3H]thymidine uptake) and steady state levels of both IL-6 and IL-6R mRNA by competitive PCR (C-PCR). Proliferation of U266 cells was decreased markedly by IL-6 antisense ODN in the absence of IL-6, but not in its presence. In contrast, IL-6R antisense ODN inhibited proliferation of U266 cells in both the presence and absence of IL-6. As anticipated, neither IL-6 nor IL-6R antisense ODN had an effect on RPMI 8226 proliferation. C-PCR demonstrated a marked and specific decrease of IL-6 and IL-6R mRNA in cells exposed to IL-6 ODN and IL-6R ODN, respectively. These results suggest that IL-6R antisense ODN may be a more effective inhibitor of IL-6-stimulated cells than IL-6 antisense in a therapeutic setting.
Insights
Interleukin-6 receptor (IL-6R) antisense oligodeoxynucleotides (ODNs) effectively inhibited myeloma cell proliferation, suggesting IL-6R targeted therapy may be more potent than IL-6 inhibition alone.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Interleukin-6 (IL-6) promotes the growth of various tumors, including lymphoma and myeloma.
- Targeting IL-6 could potentially reduce tumor progression.
Purpose of the Study:
- To investigate the efficacy of IL-6 and IL-6 receptor (IL-6R) antisense oligodeoxynucleotides (ODNs) in inhibiting myeloma cell proliferation.
- To compare the effectiveness of IL-6 versus IL-6R antisense ODNs as potential therapeutic agents.
Main Methods:
- Utilized IL-6 responsive (U266) and nonresponsive (RPMI 8226) myeloma cell lines.
- Assessed cell proliferation via [3H]thymidine uptake.
- Quantified IL-6 and IL-6R mRNA levels using competitive PCR (C-PCR).
Main Results:
- IL-6R antisense ODN inhibited U266 cell proliferation irrespective of IL-6 presence.
- IL-6 antisense ODN showed inhibitory effects only in the absence of IL-6.
- Neither ODN affected RPMI 8226 cell proliferation, confirming specificity.
- C-PCR confirmed specific mRNA reduction for IL-6 and IL-6R following respective ODN treatment.
Conclusions:
- IL-6R antisense ODN demonstrates significant potential as a therapeutic strategy for IL-6-driven myeloma.
- IL-6R targeted inhibition may offer superior efficacy compared to direct IL-6 inhibition in certain myeloma contexts.
